# Evaluation of [18F] FMH3 and PET as a Marker of Histamine-3 Receptor Activity in Subjects With AD Compared w/ HC

> **NCT01268020** · EARLY_PHASE1 · COMPLETED · sponsor: **Institute for Neurodegenerative Disorders** · enrollment: 5 (actual)

## Conditions studied

- Alzheimer Disease

## Interventions

- **DRUG:** [18F]-FMH3

## Key facts

- **NCT ID:** NCT01268020
- **Lead sponsor:** Institute for Neurodegenerative Disorders
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-12
- **Primary completion:** 2012-10
- **Final completion:** 2012-10
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2013-11-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01268020

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01268020, "Evaluation of [18F] FMH3 and PET as a Marker of Histamine-3 Receptor Activity in Subjects With AD Compared w/ HC". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT01268020. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*